Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | CASP1 | P29466 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29103604 | 0.89 | ALDH1A1 (0.43) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL29006686 | 0.89 | ALDH1A1 (0.42) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL30839745 | 0.84 | ALDH1A1 (0.65) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL63910 | 0.84 | ALDH1A1 (0.65) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL16280579 | 0.84 | ALDH1A1 (0.65) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL29777463 | 0.84 | ALDH1A1 (0.65) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL30839804 | 0.84 | CYP3A4 (0.48) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL29683594 | 0.84 | CYP3A4 (0.48) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL3784789 | 0.84 | CYP3A4 (0.48) | ALDH1A1CASP1PDE10APOLBMAPT | |
| SCHEMBL5437682 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CASP1PDE10APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113316-A1 | DEVICE, METHOD AND KIT FOR THE DETECTION OF DIFFERENT MARKERS IN DIFFERENT CELLULAR OR MOLECULAR TYPES AND THEIR QUANTIFICATIONS | MAZZEO ALESSANDRA (IT) | 2014-04-24 | — | — | US | claimed |
| JP-63091563-A | — | — | None | — | — | JP | disclosed |
| US-20260035433-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | AKSTON BIOSCIENCES CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035414-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | UNITED STATES GOVERNMENT | 2026-02-05 | — | — | US | disclosed |
| US-20260035415-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | UNITED STATES GOVERNMENT | 2026-02-05 | — | — | US | disclosed |
| EP-4676530-A2 | NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | Vakston, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12454565-B2 | PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use | AKSTON BIOSCIENCES CORPORATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250296978-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION | 2025-09-25 | — | — | US | disclosed |
| WO-2024186803-A2 | NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20230149448-A1 | METHODS FOR PREVENTING AND TREATING RESPIRATORY INFECTIONS VIA MODIFICATION OF VIRUS RECEPTOR BINDING DOMAINS USING HYPOHALOUS ACIDS | BT MANUFACTURING, LLC | 2023-05-18 | — | — | US | disclosed |
| US-5932430-A | DETECTING HELIOBACTER PYLORI ANTIGENS SAMPLE USING SENSITIVE AND ACCURATE SANDWICH ASSAY | MERIDIAN DIAGNOSTICS, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5871942-A | HELICOBACTER FOR GASTROINTESTINAL DISORDERS AND POLYCLONAL ANTIBODIES | MERIDIAN DIAGNOSTICS, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1998039647-A1 | ASYMMETRICAL FLOW-FIELD FLOW FRACTIONATING DEVICE | KLEIN THORSTEN (DE) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998027115-A1 | OIL BODIES AND ASSOCIATED PROTEINS AS AFFINITY MATRICES | SEMBIOSYS GENETICS INC. (CA) | 1998-06-25 | — | — | WO | disclosed |
| US-5716791-A | DILUTION; USING A POLYCLONAL ANTIBODY | MERIDIAN DIAGNOSTICS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| CN-1165299-A | Immunoassay for helicobacter pylori in fecal specimens | MERIDIAN DIAGNOSTICS INC (US) | 1997-11-19 | — | — | CN | disclosed |
| EP-0806667-A1 | Immunoassay for h. pylori in fecal specimens | MERIDIAN DIAGNOSTICS, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0180564-B1 | IMMUNOGENIC COMPLEX, A METHOD FOR PRODUCING THE SAME, AND THE USE THEREOF AS AN IMMUNE STIMULANT, VACCINES AND REAGENTS | Morein, Bror (SE) | 1991-07-17 | — | — | EP | disclosed |
| EP-0407172-A1 | Aromatic polyimide separation membrane | MITSUBISHI KASEI CORPORATION (JP) | 1991-01-09 | — | — | EP | disclosed |
| JP-S6391563-A | EXAMINATION OF PROTEIN SPECIFIC ANTIGEN DERIVED FROM BACTERIA | NITSUSUI SEIYAKU KK | 1988-04-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035415-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | HM13, MYOF, SMN1; SMN2 | ALDH1A1 4843/4885CASP1 1523/4885PDE10A 4850/4885 |
| US-20260035433-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | PDCD1LG2, CD274, PDCD1 | ALDH1A1 3953/4885CASP1 1861/4885PDE10A 4047/4885 |
| US-20260035414-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | SMN1; SMN2, FUS, MORF4L1 | ALDH1A1 4845/4885CASP1 1254/4885PDE10A 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.